Gam1983/iStock through Getty Pictures
Eli Lilly (NYSE:LLY) is the load loss drug inventory with essentially the most potential for upside, in accordance with Searching for Alpha’s July Sentiment Survey.
July’s Sentiment Survey by Searching for Alpha is out, overlaying what’s scorching within the markets, the financial system and different present themes.
In line with the survey, a majority of investor respondents (40.2% of 823 responses) see Eli Lilly (LLY) as the load loss drug firm with essentially the most upside.
Novo Nordisk (NVO) ranked proper underneath, receiving 30.7% of the vote, with 253 respondents saying it was the load loss drug inventory with essentially the most upside potential.
Then, 8.9% of buyers respondents (73 of them) mentioned it was Amgen (AMGN), adopted by 7.2% of them (or 59 respondents) naming AstraZeneca (AZN) as the load loss drug inventory with essentially the most upside, and after that Viking Therapeutics (VKTX), with 6.2% or 51 respondents.
Different weight reduction drug shares talked about, getting underneath 2% of the vote, included Altimmune (ALT), Pfizer (PFE), AbbVie (ABBV), Zealand Pharma (OTCPK:ZLDPF), Corbus Prescription drugs (CRBP), Ventyx Biosciences (VTYX), and Construction Therapeutics (GPCR).
Right here is final month’s survey.
